SUKRAN SENYUREK¹, SEZER SAGLAM^2,*, ESRA KAYTAN SAGLAM³, HAKAN YANAR⁴, KAAN GOK⁴, DIDEM TASTEKIN⁵, CANAN KOKSAL AKBAS⁶, NERGIZ DAGOGLU SAKIN³, GULBIZ DAGOGLU KARTAL⁷, EMRE BALIK⁸, METIN KESKIN⁴, YASEMIN SANLI⁹, MINE GULLUOGLU¹⁰, ZULEYHA AKGUN¹¹

Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351 - 21 July 2023

Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >

Nishant Patel¹, Jason Woo¹, Michael A. Liss¹, Kerrin L. Palazzi¹, J. Michael Randall², Reza Mehrazin³, Ramzi Jabaji¹, Hossein S. Mirheydar¹, Kyle Gillis¹, Hak J. Lee¹, Anthony L. Patterson³, Christopher J. Kane¹, Frederick Millard², Ithaar H. Derweesh¹

Canadian Journal of Urology, Vol.23, No.2, pp. 8227-8233, 2016

Abstract Introduction: To compare surgical complications and tyrosine kinase inhibitor (TKI)-toxicities in patients who underwent primary cytoreductive nephrectomy (CN) followed by adjuvant TKI therapy versus those who underwent neoadjuvant TKI therapy prior to planned CN for metastatic renal cell carcinoma (mRCC).
Materials and methods: Two-center retrospective analysis. Sixty-one mRCC patients underwent TKI therapy with sunitinib between July 2007 to January 2014. Patients were divided into three groups: primary CN followed by adjuvant TKI (n = 27, Group 1), neoadjuvant TKI prior to CN (n = 21, Group 2), and primary TKI alone (no surgery, n = 13, Group… More >

Michelle L. Ramirez¹, Thomas E. Keane², Christopher P. Evans¹

Canadian Journal of Urology, Vol.14, Suppl.6, pp. 10-18, 2007

Abstract Androgen deprivation therapy has been the mainstay of treatment for men with metastatic prostate cancer and now plays a more active role in the management of less advanced cancers as neoadjuvant and adjuvant treatment. Investigative uses include primary therapy for patients unsuitable for definitive therapy and as a complement to ablative procedures, brachytherapy, and chemotherapy. Intermittent androgen deprivation therapy is being considered as an alternative to continuous therapy and further evaluated as triple 10 androgen blockade in conjunction with finasteride. Many accepted and potential management schemes incorporating hormonal therapy are increasingly employed despite indeterminate indications More >

Jonathan I. Izawa^1,2,3, Joseph L. Chin^1,2,3, Eric Winquist^2,4

Canadian Journal of Urology, Vol.13, Suppl.3, pp. 48-53, 2006

Abstract Introduction: The ability of cystectomy to cure patients with muscle-invasive transitional cell carcinoma of the bladder (TCC) is diminished by the presence of occult micrometastases. Chemotherapy contributes to cure to the extent that it may eradicate these micrometastases. In the absence of methods to preoperatively stage TCC precisely or assess tumor biology, we review the current literature regarding the timing of cystectomy and use of perioperative chemotherapy. Based on this data, we suggest optimal and feasible strategies for treating TCC in a resource-constrained environment.
Materials and methods: Systematic reviews of TCC were sought using electronic databases to… More >